- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02583659
The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Establish a clinical database for the advanced gastric cancer patients treated with first-line combined chemotherapy in Tongji hospital.
1.1.Data including age, gender, smoking state, karnofsky performance score(KPS), disease history, clinical stage, primary tumor site, metastasis site, surgery, first-line chemotherapy, therapy after failure of first-line treatment, radiotherapy, toxicity, survival time, the time of free of progress, response were collected.
1.2.The peripheral blood samples were collected for further biomarker reserch.
- Kaplan-Meier and Cox model will be used to analyze the overall survival(OS) and progression-free survival(PFS) of advanced gastric cancer.
- Extract Deoxyribonucleic acid(DNA) from the the peripheral blood and research biomarkers related to the first-line combined chemotherapy for AGC.
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studie Locaties
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Werving
- Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
Hoofdonderzoeker:
- Xianglin Yuan, MD,PHD
-
Contact:
- Xianglin Yuan, MD,PHD
- Telefoonnummer: 1 13667241722
- E-mail: yxl@medmail.com.cn
-
Contact:
- Suxian Wei, Master
- Telefoonnummer: 1 15927421058
- E-mail: wsxattj@126.com
-
Onderonderzoeker:
- Suxian Wei, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Histopathology or cytopathology proven gastric cancer or gastroesophageal adenocarcinoma;
- Unresectable locally advanced, or recurrent, or metastasis disease;
- Chemotherapy-naive or disease progress at least 6 months after adjuvant chemotherapy completed.
- Life expectancy of at least 3 months;
- ECOG score 0-2;
- Voluntarily signed the informed consent.
Exclusion criteria:
- Previously treated with first-line chemotherapy;
- First-line chemotherapy with single drug.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
---|
Combined chemotherapy
AGC patients treated with first-line combined chemotherapy
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Overall survival(OS) . overall survival Overall survival(OS)
Tijdsspanne: From date of enrollment until the date of death from any cause, assessed up to 60 months
|
From date of enrollment until the date of death from any cause, assessed up to 60 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Progression-free survival(PFS)
Tijdsspanne: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
Objective response rate(ORR)
Tijdsspanne: The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
|
The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
|
Disease control rate(DCR)
Tijdsspanne: The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year
|
The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Tijdsspanne: Through first-line treatment completion,up to 24 weeks.
|
Through first-line treatment completion,up to 24 weeks.
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Xianglin Yuan, MD,PHD, Tongji Hospital
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- TJCC004
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Maagkanker
-
RSP Systems A/SVoltooid
-
Medtronic - MITGVoltooid
-
State University of New York - Upstate Medical...BeëindigdGastric Bypass-statusVerenigde Staten
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)IngetrokkenGastric Bypass-operatie
-
Olympus Corporation of the AmericasUnity Health TorontoVoltooid
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaVoltooidRoux en Y Gastric BypassVerenigde Staten
-
North Dakota State UniversityNational Institutes of Health (NIH)VoltooidRoux en Y Gastric Bypass ChirurgieVerenigde Staten
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaVoltooidSleeve gastrectomie | Roux en Y Gastric BypassVerenigde Staten
-
Medical University of South CarolinaVoltooidGastric Bypass Chirurgie PijnbestrijdingVerenigde Staten
-
Rijnstate HospitalVoltooid